| 42.95 2.11 (5.17%) | 09-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 53.03 | 1-year : | 60.03 |
| Resists | First : | 45.4 | Second : | 51.4 |
| Pivot price | 42.87  |
|||
| Supports | First : | 35.7 | Second : | 29.7 |
| MAs | MA(5) : | 42.32 |
MA(20) : | 44.16 |
| MA(100) : | 36.64 |
MA(250) : | 35.89 |
|
| MACD | MACD : | -0.5 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 43.6 |
D(3) : | 42.8 |
| RSI | RSI(14): 49.5 |
|||
| 52-week | High : | 56 | Low : | 21.51 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ RNA ] has closed below upper band by 49.2%. Bollinger Bands are 8.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 43.04 - 43.25 | 43.25 - 43.43 |
| Low: | 40.22 - 40.45 | 40.45 - 40.65 |
| Close: | 42.59 - 42.96 | 42.96 - 43.29 |
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
Tue, 23 Sep 2025
Avidity Biosciences (NASDAQ:RNA) Insider Sells $89,600.64 in Stock - MarketBeat
Mon, 22 Sep 2025
Evercore ISI Cuts Avidity Biosciences (NASDAQ:RNA) Price Target to $65.00 - MarketBeat
Sun, 21 Sep 2025
Mirador Capital Partners LP Grows Stock Position in Avidity Biosciences, Inc. $RNA - MarketBeat
Wed, 17 Sep 2025
Roth Capital Initiates Coverage of Avidity Biosciences (RNA) with Buy Recommendation - Nasdaq
Mon, 15 Sep 2025
$690 Million Raised: Biotech Avidity Biosciences Closes Massive Public Offering for RNA Therapeutics - Stock Titan
Sat, 13 Sep 2025
Avidity Biosciences (RNA) Gets 9% Boost from Higher PT, Rating - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 146 (M) |
| Held by Insiders | 1.0783e+008 (%) |
| Held by Institutions | 4.5 (%) |
| Shares Short | 16,210 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -5.1874e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -4 % |
| Return on Assets (ttm) | 448.7 % |
| Return on Equity (ttm) | -24.1 % |
| Qtrly Rev. Growth | 1.073e+007 % |
| Gross Profit (p.s.) | 88.98 |
| Sales Per Share | -38.15 |
| EBITDA (p.s.) | -4.03747e+008 |
| Qtrly Earnings Growth | -3.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -490 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -1.13 |
| Price to Cash Flow | 4.3 |
| Dividend | 0 |
| Forward Dividend | 1.757e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|